Key Drivers
- Strong Liquidity
- Stable Margins
- Expense Pressure
AIAI Summary
TCMD has shifted from a stable balance-sheet story to a high-expectation execution story: lymphedema growth and the new AffloVest launch need to keep outpacing airway-clearance noise and weak quarterly cash conversion, because the stock already prices in improvement and could de-rate quickly if operating leverage stalls.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Stable Margins
- •Expense Pressure
TCMD looks financially sturdy with ample liquidity, solid but modest profitability and cash generation, yet its premium valuation and expense pressure limit upside.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Key support
- •Failed rally
TCMD remains in a bearish downtrend over the last month, with a failed rally near $29.50-$30.14 turning that area into resistance and $23.71 the key support.
Sharp rally to $30.14 on 2026-08-04 quickly reversed, signaling a failed breakout
Sentiment & News
Key News Insights:
- •EPS Beat
- •Revenue Growth
- •Outlook Update
TCMD delivered a strong Q2 with revenue growth, improved profitability, and a $0.34 EPS beat, though it updated full-year guidance to reflect temporary inventory headwinds in airway-clearance.
The results are likely supportive for TCMD, with the earnings beat and core business strength offset only partly by a short-term guidance adjustment
Similar Companies in Healthcare
Other companies in the same sector with AI ratings